These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31387791)

  • 1. Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D
    Chen PJ; Taylor M; Griffin SA; Amani A; Hayatshahi H; Korzekwa K; Ye M; Mach RH; Liu J; Luedtke RR; Gordon JC; Blass BE
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2690-2694. PubMed ID: 31387791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.
    Leopoldo M; Berardi F; Colabufo NA; De Giorgio P; Lacivita E; Perrone R; Tortorella V
    J Med Chem; 2002 Dec; 45(26):5727-35. PubMed ID: 12477356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
    Grundt P; Prevatt KM; Cao J; Taylor M; Floresca CZ; Choi JK; Jenkins BG; Luedtke RR; Newman AH
    J Med Chem; 2007 Aug; 50(17):4135-46. PubMed ID: 17672446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse.
    Mason CW; Hassan HE; Kim KP; Cao J; Eddington ND; Newman AH; Voulalas PJ
    J Pharmacol Exp Ther; 2010 Jun; 333(3):854-64. PubMed ID: 20228156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.
    Riddle LR; Kumar R; Griffin SA; Grundt P; Newman AH; Luedtke RR
    Neuropharmacology; 2011; 60(2-3):284-94. PubMed ID: 20850462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
    Gyertyán I; Kiss B; Gál K; Laszlovszky I; Horváth A; Gémesi LI; Sághy K; Pásztor G; Zájer M; Kapás M; Csongor EA; Domány G; Tihanyi K; Szombathelyi Z
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1268-78. PubMed ID: 17170312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, in silico, and in vitro studies of novel dopamine D
    Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
    Kołaczkowski M; Marcinkowska M; Bucki A; Śniecikowska J; Pawłowski M; Kazek G; Siwek A; Jastrzębska-Więsek M; Partyka A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
    Eur J Med Chem; 2015 Mar; 92():221-35. PubMed ID: 25557493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.
    Cioffi CL; Wolf MA; Guzzo PR; Sadalapure K; Parthasarathy V; Dethe D; Maeng JH; Carulli E; Loong DT; Fang X; Hu M; Gupta P; Chung M; Bai M; Moore N; Luche M; Khmelnitsky Y; Love PL; Watson MA; Mhyre AJ; Liu S
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1257-61. PubMed ID: 23380375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
    Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
    Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y; Min C; Acharya S; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity.
    Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR
    ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors.
    Leopoldo M; Lacivita E; De Giorgio P; Colabufo NA; Niso M; Berardi F; Perrone R
    J Med Chem; 2006 Jan; 49(1):358-65. PubMed ID: 16392820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11C-labeling of n-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide derivatives and evaluation as potential radioligands for PET imaging of dopamine D3 receptors.
    Turolla EA; Matarrese M; Belloli S; Moresco RM; Simonelli P; Todde S; Fazio F; Magni F; Kienle MG; Leopoldo M; Berardi F; Colabufo NA; Lacivita E; Perrone R
    J Med Chem; 2005 Nov; 48(22):7018-23. PubMed ID: 16250661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands.
    Tu Z; Li S; Cui J; Xu J; Taylor M; Ho D; Luedtke RR; Mach RH
    J Med Chem; 2011 Mar; 54(6):1555-64. PubMed ID: 21348515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
    Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P
    J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.
    Martelle JL; Claytor R; Ross JT; Reboussin BA; Newman AH; Nader MA
    J Pharmacol Exp Ther; 2007 May; 321(2):573-82. PubMed ID: 17272677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability.
    Chen J; Jiang C; Levant B; Li X; Zhao T; Wen B; Luo R; Sun D; Wang S
    ChemMedChem; 2014 Dec; 9(12):2653-60. PubMed ID: 25338762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
    Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
    J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.